MedTrace Logo

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2023-08-01

Study results available
· View outcomes & findings →

Summary

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Conditions

Interventions

BIOLOGICAL

Enapotamab vedotin (HuMax-AXL-ADC)

Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.

Sponsors & Collaborators

  • Genmab

    lead INDUSTRY

Principal Investigators

  • Ignace Vergote, Professor · Universitair Ziekenhuizen Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-23
Primary Completion
2021-11-12
Completion
2021-11-12
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Denmark
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02988817 on ClinicalTrials.gov